Drugs / CYD-1,3,4 Dengue (Vero)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00740155 | Aug 2008 → Oct 2009 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYD-1,3,4 Dengue (Vero) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00740155 ↗ |
| Known as | CYD-1;3;4 | “Two groups received an injection at each timepoint of a tetravalent blend of CYD-1;3;4 and a VERO cell derived, live attenuated vaccine against serotype 2 (VDV-2), or the...” PMID 25483647 ↗ 2014 |
| Modality | Vaccine | “live attenuated vaccine” PMID 25483647 ↗ 2014 |
| Route | Subcutaneous | “0.5 mL, Subcutaneous (SC)” NCT00740155 ↗ |